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Chronic hepatitis B (CHB) infection is still becomes 
a major problem in the world and the most prevalent 
etiology of advanced liver disease in Indonesia. 
Vertical route of transmission is the predominant 
route in Asian countries. The different phases of CHB 
patients who seek for medical consultation would 
give the different prognosis, and sometimes it is also 
dif cult to  nd out in which stage of the disease in 
some of those patients as might be in uenced by many 
factors, such as co-infected with other viral hepatitis, 
other metabolic liver condition (non-alcoholic fatty 
liver disease), hepatotoxic drugs, etc.1,2,3,4,5
The routine biomarkers such as ALT level and 
hepatitis B virus (HBV) DNA quantitative have 
been used for many years either for diagnosis or 
monitoring the progression of the disease. However, 
these biomarkers are seemed not very ideal markers 
liver disease progression might continue even when 
the biomarkers showed inactive carrier stage.5,6,7 The 
main key players in CHB infection are covalently 
closed circular (ccc) DNA and Pre-genomic (Pg) RNA 
where both of players modulate viral replication in the 
hepatocyte and these markers can be de ned as the 
true markers of viral replication activity. Studies have 
shown that quantitative serum of HBV DNA could 
not predict the virion intrahepatic and its replication 
especially in the small amount. Other factor such as 
viral mutation also might in uence the history of the 
disease. The dif culty of assessing these intrahepatic 
markers, it should be through invasive procedure 
(liver biopsy) where most of the patients are reluctant 
to undergo this procedure. The other advantage of 
performing liver biopsy is that the liver condition might 
be better predicted or we could even know very well 
when the treatment should really be considered.8,9,10 
In the era of fatty liver disease, liver biopsy could 
become more and more important for assessing the 
liver condition instead the liver stiffness measurement 
using new technology such as Fibroscan. 
Revisiting old marker becoming new marker such 
as surface antigen (HBsAg) recently made a better 
life in the liver world. Many studies have shown the 
utility this new marker as a promising tool in the CHB 
management. Quanti cation of HBsAg seemed can 
be a predictive tool for immune response in treatment 
monitoring, but when we discuss about immune 
response, only pegylated interferon (Peg-interferon) 
treatment might be bene t of this new marker. The 
different of genotype makes a new controversial, as 
the genotype might give an important role in CHB 
progression.11,12,13,14
At the end, we need to see patient to patient’s history 
because each CHB patient might have different prognosis 
as the family history and genetic polymorphism are also 
play important role in liver disease progression. The 
rational of using new marker should be reconsidered 
when we are in the real clinical practice. Looking and 
investigate the new concept of CHB management are 
always challenging as the disease is quite complicated 
and sometimes unpredictable. 
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